What's new

Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Status: Authorised

Apr 14, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Capvaxive, pneumococcal polysaccharide conjugate vaccine (21-valent), Date of authorisation: 24/03/2025, Status: Authorised
Read More

Tags:

Previous Article

J&J MedTech reports first clinical cases with Ottava surgical robot

Next Article

Last chance to complete Drapers’ workplace harassment survey

Related Posts

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0

Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir,ritonavir, Date of authorisation: 28/01/2022, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 14, 2025  0

Consolidated 3-year rolling work plan for the Oncology ...

Feb 21, 2025  0